Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.46 |
| ▸ | GABRD | O14764 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.46 |
| ▸ | GABRE | P78334 | 3/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.46 |
| ▸ | G6PD | P11413 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045297 | 1.00 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10125295 | 0.82 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12885835 | 0.82 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10125292 | 0.78 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31267268 | 0.77 | MEN1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10125299 | 0.77 | MEN1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9009451 | 0.77 | MEN1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9009430 | 0.77 | MEN1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12883265 | 0.75 | CYP19A1 (0.43) | CYP3A4MEN1LMNAKMT2AMAPK1 | |
| SCHEMBL13821647 | 0.73 | UGT2B7 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575136-B2 | 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7893043-B2 | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1 alpha ,25-dihydroxyvitamin D3; exhibits relatively high transcription activity as well as pronounced activity in arresting proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7704981-B2 | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704982-B2 | 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-7648972-B2 | 2-methylene-1α-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648973-B2 | 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100009942-A1 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-01-14 | — | — | US | disclosed |
| US-20070249569-A1 | 2-Methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238702-A1 | 2-Methylene-1Alpha-Hydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238701-A1 | 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238706-A1 | Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-7241750-B2 | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238702-A1 | 2-Methylene-1Alpha-Hydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | GABRP 2723/4885GABRD 520/4885GABRA1 2375/4885 |
| US-20070238706-A1 | Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis | SHBG, HLA-DRB1, BRCA1 | GABRP 3652/4885GABRD 3435/4885GABRA1 2553/4885 |
| US-20070238701-A1 | 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | GABRP 2699/4885GABRD 666/4885GABRA1 2574/4885 |
| US-20070249569-A1 | 2-Methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses | CYP27B1, CYP24A1, CYP2R1 | GABRP 2735/4885GABRD 481/4885GABRA1 1939/4885 |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | GABRP 3258/4885GABRD 753/4885GABRA1 3179/4885 |
| US-20100009942-A1 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs | CYP24A1, CYP27B1, VDR | GABRP 2031/4885GABRD 343/4885GABRA1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.